WallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRL

Based on 9 analysts offering 12 month price targets for Charles River Laboratories International Inc.
Min Forecast
$334.00-24.05%
Avg Forecast
$373.33-15.11%
Max Forecast
$465.00+5.73%

Should I buy or sell CRL stock?

Based on 10 analysts offering ratings for Charles River Laboratories International Inc.
Buy
Strong Buy
6 analysts 60%
Buy
0 analysts 0%
Hold
4 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
UBS
Top 31%
70
Strong BuyMaintains$465.00+5.73%2021-08-17
Credit Suisse
Top 27%
74
HoldMaintains$385.00-12.46%2021-07-20
Citigroup
Top 3%
98
HoldMaintains$355.00-19.28%2021-05-28
Credit Suisse
Top 3%
98
HoldMaintains$352.00-19.96%2021-05-28
JP Morgan
Top 16%
85
Strong BuyMaintains$390.00-11.32%2021-05-28
Truist Securities
Top 3%
98
Strong BuyMaintains$369.00-16.10%2021-05-25
KeyBanc
Top 7%
94
Strong BuyMaintains$360.00-18.14%2021-05-14
Morgan Stanley
Top 3%
98
Strong BuyMaintains$350.00-20.42%2021-02-22
Deutsche Bank
Top 16%
85
Strong BuyMaintains$334.00-24.05%2021-02-18
Anonymous
Citigroup
HoldDowngradesN/AN/A2020-12-16

1 of 1

Forecast return on equity

Is CRL forecast to generate an efficient return?
Company
32.89%
Industry
47.45%
Market
30.41%
CRL's Return on Equity is forecast to be high in 3 years (32.89%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?
Company
11.35%
Industry
15.94%
Market
15.13%
CRL is forecast to generate lower Return on Assets (11.35%) than the US Diagnostics & Research industry average (15.94%)
Forecast

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$10.25+29.09%
Avg 2 year Forecast
$11.72+47.55%
Avg 3 year Forecast
$13.46+69.55%
CRL's earnings are forecast to grow at a rate of 19.03% per year, which is not exceptional
Forecast

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.6B+8.84%
Avg 2 year Forecast
$3.9B+20.31%
Avg 3 year Forecast
$4.3B+32.21%
CRL's revenue is forecast to grow at a rate of 9.73% per year, which is not exceptional
Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
19.03%
Industry
16.52%
Market
18.84%
CRL's earnings are forecast to grow faster (19.03% per year) than the US Diagnostics & Research industry average (16.52%)
Forecast
CRL's earnings are forecast to grow faster (19.03% per year) than the US market average (18.84%)
Forecast
CRL's earnings are forecast to grow faster (19.03% per year) than the risk-free savings rate (1.3%)
Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
9.73%
Industry
11.12%
Market
12.2%
CRL's revenues are forecast to grow slower (9.73% per year) than the US Diagnostics & Research industry average (11.12%)
Forecast
CRL's revenues are forecast to grow slower (9.73% per year) than the US market average (12.2%)
Forecast

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 10 Wall Street analysts covering (NYSE: CRL) stock is to Buy CRL stock.

Out of 10 analysts, 6 (60%) are recommending CRL as a Strong Buy, 0 (0%) are recommending CRL as a Buy, 4 (40%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

What is CRL's earnings growth forecast for 2021-2023?

(NYSE: CRL) Charles River Laboratories International's forecast annual earnings growth rate of 19.03% is forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 16.52%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 18.84%.

Charles River Laboratories International's earnings in 2021 is $396,078,000.On average, 7 Wall Street analysts forecast CRL's earnings for 2021 to be $516,565,376, with the lowest CRL earnings forecast at $497,918,625, and the highest CRL earnings forecast at $526,644,700. On average, 7 Wall Street analysts forecast CRL's earnings for 2022 to be $590,431,704, with the lowest CRL earnings forecast at $583,592,883, and the highest CRL earnings forecast at $597,199,971.

In 2023, CRL is forecast to generate $678,464,524 in earnings, with the lowest earnings forecast at $668,763,174 and the highest earnings forecast at $688,417,857.

What is CRL's revenue growth forecast for 2021-2023?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 9.73% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 11.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.2%.

Charles River Laboratories International's revenue in 2021 is $3,273,463,000.On average, 5 Wall Street analysts forecast CRL's revenue for 2021 to be $179,559,636,422, with the lowest CRL revenue forecast at $178,290,649,481, and the highest CRL revenue forecast at $180,334,232,503. On average, 6 Wall Street analysts forecast CRL's revenue for 2022 to be $198,481,098,549, with the lowest CRL revenue forecast at $188,957,094,527, and the highest CRL revenue forecast at $202,596,940,271.

In 2023, CRL is forecast to generate $218,102,519,358 in revenue, with the lowest revenue forecast at $207,525,729,903 and the highest revenue forecast at $226,118,253,277.

What is CRL's forecast return on assets (ROA) for 2021-2024?

(NYSE: CRL) forecast ROA is 11.35%, which is lower than the forecast US Diagnostics & Research industry average of 15.94%.

What is CRL's Price Target?

According to 9 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $373.33, with the highest CRL stock price forecast at $465.00 and the lowest CRL stock price forecast at $334.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could stay at $373.33 by Aug 17, 2022. The average Charles River Laboratories International stock price prediction forecasts a potential downside of N/A from the current CRL share price of $439.79.

What is CRL's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: CRL) Charles River Laboratories International's current Earnings Per Share (EPS) is $7.94. On average, analysts forecast that CRL's EPS will be $10.25 for 2021, with the lowest EPS forecast at $9.88, and the highest EPS forecast at $10.45. On average, analysts forecast that CRL's EPS will be $11.72 for 2022, with the lowest EPS forecast at $11.58, and the highest EPS forecast at $11.85. In 2023, CRL's EPS is forecast to hit $13.46 (min: $13.27, max: $13.66).

What is CRL's forecast return on equity (ROE) for 2021-2024?

(NYSE: CRL) forecast ROE is 32.89%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.